Hikma acquires six injectable products in Europe

London, 24 June 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that it has agreed to acquire a portfolio of six injectable products and their related customer contracts from Pfizer Inc. (NYSE: PFE).

Press Release Corporate 24 June 2016

The acquired portfolio includes one anti-infective, one anti-fungal and four oncology products. Five of the products are currently sold across several markets in Europe. The divestiture of these products was mandated by the European Commission as a condition to Pfizer’s acquisition of Hospira and the European Commission has announced its approval of Hikma as purchaser of the portfolio.

Said Darwazah, Chairman and Chief Executive Officer of Hikma, said: “This acquisition supports our strategy to strengthen our marketed product portfolio of specialised generic injectables and create new opportunities for growth across our markets.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.